Golden Recursion Inc. logoGolden Recursion Inc. logo
Advanced Search
Sofinnova Partners

Sofinnova Partners

An independent venture capital firm based in Paris that provides funding for seed, early stage and late stage biotechnology ventures

Sofinnova Partners is an independent venture capital firm from Paris, France that provides funding for seed, early stage and late stage ventures. Founded in 1972, the firm has financed and has partnered with almost 500 companies. They invest in companies in the life science sector, especially those that work with biopharmaceuticals, biotech, medical devices, and industrial biotechnology. It usually invests in Round A, and leads its portfolio companies until exit.

The company prioritizes projects with intellectual property and whose founders have pharmaceutical or industrial experience. They invest in start-ups usually from the academic world, as well as spin-offs. The firm also seeks to invest in late pre-clinical and clinical therapeutic companies across the United States and Europe.They work with entrepreneurs to secure initial funding, help their partner companies build teams, find customers, and complete acquisitions and IPOs.

Timeline

July 30, 1972
Sofinnova Partners is founded.

Invested in

Associated Investment Funds

Patents

Funding Rounds Participated In

Further Resources

Title
Author
Link
Type
Date

News

Title
Author
Date
Publisher
Description
Conor Hale
July 13, 2021
FierceBiotech
Shortly after raising an oversubscribed capital round for clinical-stage companies, Sofinnova Partners is back to announce €63 million ($75 million) for its third acceleration fund aimed at nascent medtech developers.
Mnemo Therapeutics
June 16, 2021
www.prnewswire.com:443
/PRNewswire/ -- Mnemo Therapeutics, ein Biotechnologie-Unternehmen, das leistungsstarke Zelltherapien entwickelt, die eine neuartige...
Heather McKenzie
June 16, 2021
BioSpace
The Paris-based biotech will use the funds to create targeted immuno-oncology treatments for a broader range of patients with its next-generation CAR-T and epigenetics platform.
FinSMEs
June 16, 2021
FinSMEs
About | Advertise | Contact | Disclaimer | News | The Daily Deal Newsletter FinSMEs.com by FinSMEs is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License.
Mnemo Therapeutics
June 16, 2021
www.prnewswire.com:443
/PRNewswire/ -- Mnemo Therapeutics, a biotechnology company developing powerful cell therapies using a novel target identification engine, stronger T cells and...
SHOW MORE

References

Golden logo
By using this site, you agree to our Terms & Conditions.